Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anxiety and Depression in Patients With Hematologic Malignancies
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
Assessment of Anxiety and Depression Status in Patients with Hematologic Malignancies
Official title: An Observational Prospective Cohort Study of Anxiety and Depression in Patients With Hematologic Malignancies
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2026-10-20
Completion Date
2030-12-01
Last Updated
2026-10-20
Healthy Volunteers
No
Conditions
Interventions
Baseline Anxiety and/or Depression
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS), consisting of two 7-item subscales (HADS-A and HADS-D), each ranging from 0 to 21. Baseline anxiety and/or depression status will be the exposure of interest. Psychological assessments will be repeated at 3, 6, and 12 months after treatment initiation. No study-assigned anticancer or psychological treatment will be administered.
Locations (1)
the First Affilaited Hospital of Xiamen University
Xiamen, Fujian, China